Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the Resura™ Prenatal Test. Current practice for diagnosing a fetus at-risk of an inherited disease involves undergoing invasive procedures.

Presenting at the BTIG, Raymond James, and Cowen health care conferences. SAN DIEGO, February 26, 2019  – Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms,

That's how many clear and actionable answers have been provided to patients with Progenity’s genetic testing since the launch of our next-generation sequencing platform in 2014.

Know more. Learn how we have improved our Innatal® Prenatal Screen. Progenity is dedicated to continuous product improvement. We have upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry. In-depth verification and validation testing of the Innatal assay,

Company focused on diagnostic and therapeutic precision medicine solutions in prenatal and perinatal healthcare, oncology, and gastroenterology. SAN DIEGO, February 21, 2019  -- Progenity, Inc., a privately held biotechnology company, today announced the expansion of its board of directors with